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ABSTRACT 
 
A series of 1,2,4-oxadiazolymethyl sydnones carrying azido group 
were synthesized and subjected to react with a variety of alkenic 
and acetylenic dipolarophilic reagents; N-phenyl maleimide, 
phenyl vinyl sulfone, and phenyl propiolic acid. All the new 
products are identified by spectral/physical data including high-
resolution mass measure-ments and X-ray diffraction data. 
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Introduction 
 
Sydnones are among the important classes of mesoionic systems which were discovered 
by Earl and Mackney[1] and they have been receiving an increasing interest over the 
decades due to their capability to be converted into heterocycles with potent biological 
activities.[2–4] The electrophilic substitution of sydnones in C4 position is a well-known 
method for the preparation of a wide range of 4-heterocycle-substituted sydnones.[5,6] 
 
1,2,4-Oxadiazole derivatives are also important skeletons of biologically or pharmaco-
logically important compounds. For example, muscarinic agonists, histamine H3 antagonists, 
antitumoral, anti-inflammatory, and antimycobacterium tuberculosis agents containing a 
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1,2,4-oxadiazole ring are among them.[7–12] On the other hand, triazole rings have 
also attracted remarkable attention due to their biological activities such as antifungal, 
anti-convulsant agents and especially popular in designing anticancer agents.[13–17] 
 
1,3-Dipolar cycloaddition route is a valuable process to assemble molecules having 
fragments in biologically active agents of five-membered nitrogen heterocycles. From a 
synthetic standpoint, it may be considered worthy and in principle, available by a sequence 
involving sydnone functionalization with azido group followed by cycloaddition. 
 
Taking account of the above considerations together with our continuing interest in the 
1,3-dipolar cycloaddition chemistry of various ylides leading to triazoles and 
spiropyrroles,[18–21] we focus herein on the synthesis of oxadiazolyl-substituted sydnones 
starting from sydnones and their carboxamidoxime derivatives which were subsequently 
converted into azidomethyl compounds. The latter were engaged in a series of representa-
tive electron-deficient alkenes and alkynes, and their cycloaddition reactions. These series 
of sydnones were reacted with three representative dipolarophiles: N-phenyl maleimide, 
phenyl vinyl sulfone, and phenyl propiolic acid. 
 
Results and discussion 
 
N-Aryl sydnones 5a–f have been synthesized starting from 4-substituted anilines 1 
through cyclodehydration of corresponding N-nitroso α-amino carboxylic acids 4 
according to the previously reported procedures (Scheme 1).[22,23] In this way, we 
have prepared 6 sydnone derivatives. 
 
To convert sydnones 5 into 4-carboxamidoxime derivatives 9, a reaction 
sequence has been utilized, which, first, transformed starting materials to sydnone 
aldehydes 6 by Vilsmeer–Haack formylation.[24] Aldehydes 6 were then 
transformed into aldoximes 7 which were dehydrated to give nitriles 8.[25] Sydnone 
nitriles 8 have been reacted with hydroxylamine to yield sydnone amidoximes 9 
(Scheme 2). In this way, we have prepared 3 sydnone carboxamide oximes. 
 
Sydnone-4-carboxamidoximes 9 have been converted into 5-chloromethyl-3-substitu-
tedphenyl-1,2,4-oxadiazoles 10a–c[26] by their reaction with chloroacetyl chloride in 
benzene under reflux. Sydnone azides 11a–d were obtained from the reaction of 
oxadiazoles 10a–d with NaN3 according to previously reported procedure (Scheme 3).[21] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Synthesis of N-aryl sydnones 5a–f. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of sydnone-4-carboxamidoximes 9a–d. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Synthesis of azido sydnones 11a–d. 
 
Among the important spectral characteristics of these novel compounds are azide 
and carbonyl stretching absorptions in the IR spectra at around 2100 and 1750 cm 1; 
CH2 protons and carbon at around 4.50 and 45 ppm, respectively, in the NMR spectra. 
 
One of the chloromethyl oxadiazolyl sydnones, 10c has been elucidated by 
obtaining X-Ray ORTEP view (Fig. 1). 
 
Sydnone azides 11a–c were then subjected to 1,3-dipolar cycloaddition with N-
phenyl maleimide 12 to give cycloadducts 13a–c which were absolutely identified 
by X-ray diffraction data (Scheme 4, Fig. 2). 
 
Upon examination of the IR data, strong absorptions arising from both sydnone and 
maleimide portions of the cycloadducts at around 1770–1720 cm 1 were observed. 1H 
NMR spectra also showed the methylene protons as separate doublets at around 5.55 and 
5.20 ppm, while the bridge protons resonated as doublets at 5.65 and 4.55 ppm. Carbonyl 
carbons appeared at 175–165 ppm region, bridge carbons at around 83 and 56 ppm and 
methylene carbons at 44 ppm, respectively. These results are in accord with the previous 
findings.[21] We were also able to obtain an X-ray ORTEP diagram of 13b (Fig. 2). 
 
Azido sydnones 11a and 11b were also assayed for 1,3-dipolar cycloaddition 
with electron-deficient alkene, and phenyl vinyl sulfone 14 and cycloadducts 15a,b 
were obtained in lower yields of 13 and 10%, respectively (Scheme 5). 
 
Spectral characteristics of these cycloadducts included a carbonyl absorption in the IR 
spectrum emerged from the sydnone fragment, symmetric, and asymmetric stretching 
vibrations of sulfone moiety at 1325–1140 cm 1. The proton NMR signals of the triazoline 
ring and methylene hydrogens existing in the region of 5.60–3.50 ppm were indicative. All 
these resonances coincide with the previous reports regarding the associated 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. X-ray ORTEP view of 10c. 
 
compounds.[27,28] We have utilized a number of different reaction conditions for 
other azido sydnones (11c,d) to obtain a variety of cycloadducts carrying phenyl 
sulfonyl group, but all the attempts failed, that is, no triazole products were formed. 
 
To explore the cycloaddition of novel azides with an alkyne dipolarophile, we 
used phe-nyl propiolic acid 16 and it smoothly underwent cycloaddition to afford 
the cycloadducts 17a–d with the azido sydnones 11a–d (Scheme 6). 
 
1,3-Dipolar cycloadditon of azido sydnones 11a–d with phenyl propiolic acid resulted in 
regioselective formation of 4-phenyl regioisomers (triazoline ring numbering) but not 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Cycloaddition of azido sydnones 11a–c with N-phenyl maleimide 12. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. X-ray ORTEP view of 13b. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5. Cycloaddition of azido sydnones 11a,b with phenyl vinyl sulfone 14. 
 
5-phenyl regioisomers which are supported by the X-ray diffraction data of 17b 
(Fig. 3) as well as by an earlier report utilizing electron-deficient alkyne esters.[25] 
Indicative spectral characteristics are the carbonyl absorptions of sydnone part, 
and C=N absorptions in the IR spectra. 1H NMR spectra of products showed a 
triazole proton at around 7.90 ppm and metyhylene protons at around 5.90 ppm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6. Cycloaddition of 11a–d with phenyl propiolic acid 16 affording 17a–d. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. X-ray ORTEP view of 17b. 
 
Table 1. Estimated Lipinski values for 13, 15, 17. 
 
Entry R (sydnone N3-substitution) cLogP Solubility MW TPSA Druglikeness Drug score 
        
13a C6H4-Me 3.13 4.39 472.0 157.2 0.64 0.54 
13b C6H4-OMe 3.54 4.06 488.0 166.4 2.1 0.62 
13c C6H4-Br 2.75 4.88 536.0 157.2 0.09 0.41 
15a C6H4-Me 2.11 4.28 467.0 162.3 10.6 0.33 
15b C6H4-OMe 2.52 3.95 483.0 171.6 9.09 0.34 
17a C6H4-Me 1.43 4.36 401.0 122.6 2.54 0.39 
17b C6H4-OMe 1.84 4.03 417.0 131.8 1.05 0.47 
17c C6H4-Br 1.04 4.85 465.0 122.6 3.11 0.32 
17d CH3 3.16 3.04 325.0 122.6 1.25 0.54 
 
We also attempted to perform a second cycloaddition with the sydnone 
fragment of the cycloadducts, but despite numerous trials, no reaction occurred; 
much likely to be attributed to the sterical bulkiness around the ylide that prevents 
from the approach of dipolarophiles. 
 
One of our goals associated with this work was to screen the novel products for their 
bioactivities, but, due to low amounts of the end products, it was not possible at this 
moment. However, we have made some predictions by Lipinski’s rule of five (RO5), a rule 
of thumb to evaluate druglikeness or determine if a chemical compound with a certain phar- 
 
macological or biological activity has properties that would make it a likely orally active drug in 
humans.[29–31] Below is given a table indicating the estimated Lipinski values (Table 1). In 
this regard, higher scores are related to the methoxy- and methyl-substituted adducts. 
 
Conclusion 
 
Through this work, we have demonstrated a ten-step reaction sequence leading to the 
synthesis of the novel sydnones bearing azidomethyl-1,2,4-oxadiazole fragment and their 
1,3-dipolar cycloaddition reaction with a series of electron-deficient dipolarophilic reagents; 
N-phenyl maleimide, phenyl vinyl sulfone, and phenyl propiolic acid. The compounds 13, 
15, and 17 resulted from 1,3-dipolar cycloaddition of the sydnone azides 
  
preferrentially by azide-dipolarophile reaction, but no further reactivity has been 
observed between sydnone azide cycloadducts and dipolarophiles, even if too 
many reaction conditions were assayed. 
 
Experimental 
 
Melting points were determined on a Meltemp apparatus and are uncorrected. Infrared 
spectra were obtained from KBr pellets or neat on NaCl plates for liquids and were 
recorded on a SHIMADZU FTIR-8400S spectrophotometer. NMR spectra were recorded 
on Jeol and Varian spectrometers operating at 400 MHz for 1H and at 100 MHz for 13C, all 
at 25 °C, as specified for each data set. LC–MS spectra were obtained from Waters 2695 
Alliance Micromass ZQ instrument. High-resolution mass spectra have been obtained from 
Waters Lct Premier XE oa-TOF mass spectrometer (Waters Corporation, Milford, MA, 
USA). Single-crystal X-ray diffraction data were obtained by Bruker Smart Apex II Quazar 
and Nonius Kappa CCD instruments. All chemical shifts are reported in ppm relative to 
TMS. Coupling constants (J) are reported in Hz. Routine TLC analyses were performed on 
pre-oated silica gel plates with fluorescent indicator. Flash column chroma-tography was 
performed on silica gel (230–400 mesh ASTM). A rotary TLC apparatus (Chromatotron) 
was utilized for further separation and purifications. Stain solutions of potassium 
permanganate and iodine were used for visualization of the TLC spots. 
 
Typical reaction procedure for the synthesis of 4-(5-(chloromethyl)-
1,2, 4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone (10a)[22] 
 
A solution of chloroacetylchloride (0.070 g, 0.62 mmol) in benzene (2 mL) was 
added dropwise to a solution of 3-(4-methoxyphenyl)sydnone-4-carboxamidoxime 
9a (0.360 g, 1.54 mmol) in benzene (20 mL) and the mixture was heated under 
reflux for 24 h. The progress of reaction was monitored by TLC. The reaction 
mixture was concentrated in vacuo, and the crude residue was purified by flash 
column chromatography (n-hexane:ethyl acetate; 4:1) to give 10a as a white solid. 
 
4-(5-(chloromethyl)-1,2,4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone (10a) 
 
Yield: 0.400 g, 89%. mp 155–156 °C. Rf: 0.59 (n-hexane:ethyl acetate; 1:1). IR (KBr, v:cm 
1): 3014, 2960, 1797, 1778 (sydnone C=O), 1568 (C=N), 1510, 1444, 1282, 1199, 1058, 
1010, 954, 891, 779, 750 (C–Cl). 1H NMR (400 MHz, CDCl3): δH ¼ 7.45 (d, J ¼ 8.4 Hz, 
2H), 7.41 (d, J ¼ 8.4 Hz, 2H), 4.66 (s, 2H), 2.51 (s, 3H). 13C NMR (100 MHz, CDCl3): δC ¼ 
174.5 (sydnone C=O), 158.5 (C=N), 143.6, 130.3, 124.7, 32.9 (CH2), 21.6 (CH3). LC–MS 
(80 eV) (m/z) (%): 356 ([MþCH3CNþNa]þ, 100), 293 ([MþH]þ, 48), 248 (21). HRMS: m/z 
(ESI-TOF, [MþH]þ) calcd for C12H10N4O3Cl: 293.0441; found: 293.0428. 
 
Typical reaction procedure for the synthesis of 4-(5-(azidomethyl)-
1,2, 4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone (11a)[19,23] 
 
To a stirred solution of 4-(5-(chloromethyl)-1,2,4-oxadiazol-3-yl)-3-(4-methylphenyl)syd-
none, 10a (0.400 g, 1.37 mmol) in a 10 mL of water/acetone mixture (1:4) was added 
  
 
sodium azide (0.098 g, 1.51 mmol). The resulting suspension was stirred at room 
tempera-ture for 24 h. Dichloromethane (DCM) was added to the mixture and the 
organic layer was separated. The aqueous layer was extracted with 3 � 10 mL 
aliquots of DCM and the combined organic layers were dried over sodium sulfate. 
Solvent was removed under reduced pressure to give 11a as a light yellow solid. 
 
4-(5-(azidomethyl)-1,2,4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone (11a) 
 
Yield: 0.200 g, 49%. mp 98–101 °C. Rf: 0.58 (n-hexane:ethyl acetate; 1:1). IR (KBr, v:cm 
1): 3061, 2991, 2922, 2098 (N=N¼N), 1759, 1743 (C=O), 1558 (C=N), 1508, 1435, 1319, 
1273, 1197, 1056, 1016, 960, 817, 740. 1H NMR (400 MHz, CDCl3): δH ¼ 7.44 (d, J ¼ 8.8 
Hz, 2H), 7.40 (d, J ¼ 8.8 Hz, 2H), 4.51 (s, 2H), 2.49 (s, 3H).13C NMR (100 MHz, CDCl3): 
δC ¼ 174.2 (sydnone C=O), 164.8 (C=N), 158.4 (C=N), 143.4, 131.8, 130.3, 124.5, 44.6 
(CH2), 21.5 (CH3). LC–MS (80 eV) (m/z) (%): 363 ([MþCH3CNþNa]þ, 94), 300 ([MþH]þ, 
100). HRMS: m/z (ESI-TOF, [MþH]þ) calcd for C12H10N7O3: 300.0845; found: 300.0834. 
 
Typical reaction procedure for the synthesis of 4-(5-(((3aS,6aR)-4,6-
dioxo-5-phenyl-4,5,6,6a-tetrahydropyrrolo[3,4-d][1,2,3]triazol-1(3aH)-
yl)methyl)-1,2, 4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone (13a) 
 
A mixture of N-phenyl maleimide 12 (0.030 g, 0.175 mmol) and 4-(5-(azidomethyl)-
1,2,4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone 11a (0.050 g, 0.167 mmol) was 
stirred in benzene (17 mL) and the mixture was heated under reflux for 2–4 d. The 
reaction was monitored by TLC. The reaction mixture was concentrated in vacuo, 
and the crude residue was purified by flash column chromatography (n-
hexane:ethyl acetate; 1:2) to give 13a as a light yellow solid. 
 
4-(5-(((3aS,6aR)-4,6-dioxo-5-phenyl-4,5,6,6a-tetrahydropyrrolo[3,4-d][1,2,3] 
triazol-1(3aH)-yl)methyl)-1,2,4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone (13a) 
 
Yield: 0.020 g, 25%. mp 143–144 °C. Rf: 0.19 (n-hexane:ethyl acetate; 1:1). IR (KBr, 
v:cm 1): 1766 (sydnone C=O), 1720 (C=O), 1564 (C=N), 1492, 1379, 1195, 1041, 817, 
742. 1H NMR (400 MHz, CDCl3): δH ¼ 7.48–7.38 (m, 4H), 7.35 (d, J ¼ 2.8 Hz, 2H), 
7.2 (t, J ¼ 2.0 Hz, 1H), 7.19 (t, J ¼ 1.6 Hz, 1H), 5.62 (d, J ¼ 10.8 Hz, 1H), 5.48 (d, J ¼ 
18.0 Hz, 1H), 5.22 (d, J ¼ 18.0 Hz, 1H), 4.56 (d, J ¼ 10.8 Hz, 1H), 2.51 (s, 3H). 13C 
NMR (100 MHz, CDCl3): δC ¼ 174.3 (sydnone C=O), 170.9 (C=O), 168.3 (C=O), 164.8 
(C=N), 158.1 (C=N), 143.7 (C–CH3), 131.7, 130.4, 129.5, 129.3, 126.8, 126.3, 126.0, 
124.6, 83.2 (CH), 57.0 (CH), 44.3 (CH2), 21.5 (CH3). HRMS: m/z (ESI-TOF, [MþH]þ) 
calcd for C22H17N8O5: 473.1322; found: 473.1325. 
 
Typical reaction procedure for the synthesis of 3-(4-
methylphenyl)-4-(5-((5-(phenylsulfonyl)-4,5-dihydro-1H-1,2,3-
triazol-1-yl)methyl)-1,2, 4-oxadiazol-3-yl)sydnone (15a) 
 
A mixture of phenyl vinyl sulfone 14 (0.024 g, 0.135 mmol) and 4-(5-(azidomethyl)-1,2, 
4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone 11a (0.040 g, 0.134 mmol) was stirred in 
  
 
toluene (7 mL) and the mixture was heated under reflux for 6 d. The reaction was 
moni-tored by TLC. The reaction mixture was concentrated in vacuo, and the 
crude residue was purified by flash column chromatography (n-hexane:ethyl 
acetate; 1:2) to give 15a as a light yellow solid. 
 
3-(4-methylphenyl)-4-(5-((5-(phenylsulfonyl)-4,5-dihydro-1H-1,2,3-
triazol-1-yl) methyl)-1,2,4-oxadiazol-3-yl)sydnone (15a) 
 
Yield: 8 mg, 13%. mp 84–86 °C. Rf : 0.20 (n-hexane:ethyl acetate; 1:1). IR (KBr, v:cm 1): 2958, 
2927, 2852, 1770 (sydnone C=O), 1564 (C=N), 1446, 1321 (asym SO2), 1240, 1151 (sym SO2), 
1082, 1056, 935, 821, 744. 1H NMR (400 MHz, CDCl3): δH ¼ 7.95 (dd, J ¼ 8.0, 0.4 Hz, 2H), 
7.72 (t, J ¼ 7.6 Hz, 1H), 7.60 (t, J ¼ 8.0 Hz, 2H), 7.42 (dd, J ¼ 11.6, 8.8 Hz, 4H), 5.56 (dd, J ¼ 
8.4, 7.2 Hz, 1H), 5.19 (d, J ¼ 17.6 Hz, 1H), 4.96 (d, J ¼ 17.2 Hz, 1H), 3.85 (dd, J ¼ 11.6, 7.6 
Hz, 1H), 3.52 (t, J ¼ 12.0 Hz, 1H), 2.47 (s, 3H). 13C NMR (100 MHz, CDCl3): δC ¼ 173.5 
(sydnone C=O), 164.7 (C=N), 158.2 (C=N), 143.6 (C–CH3), 136.0, 134.8, 131.7, 130.3, 129.5, 
129.3, 124.7, 95.1 (C–SO2), 44.9 (CH2), 44.2 (CH2), 21.5 (CH3). LC–MS (80 eV) (m/z) (%): 490 
([MþNa]þ, 100), 468 ([MþH]þ, 19), 459 (60). ESI-MS (80 eV) 
 
(m/z) (%): 466 ([M H], 100). HRMS: m/z (ESI-TOF, [MþH]þ) calcd for 
C20H18N7O5S: 468.1090; found: 468.1081. 
 
 
Typical reaction procedure for the synthesis of 3-(4-methylphenyl)-4-(5-((5-
phenyl-1H-1,2,3-triazol-1-yl)methyl)-1,2,4-oxadiazol-3-yl)sydnone (17a) 
 
Method A 
 
A mixture of phenylpropiolic acid 16 (0.026 g, 0.175 mmol) and 4-(5-(azidomethyl)-
1,2, 4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone 11a (0.050 g, 0.167 mmol) was 
stirred in benzene (17 mL) and the mixture was heated under reflux for 4 d. The 
reaction was monitored by TLC. But no reaction was occurred. 
 
Method B 
 
A mixture of 4-(5-(azidomethyl)-1,2,4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone 
11a (0.050 g, 0.167 mmol), catalytic amount of CuSO4·5H2O (0.002 g, 0.008 
mmol), Na-L-ascorbate (0.009 g, 0.043 mmol), and phenylpropiolic acid 16 (0.026 
g, 0.175 mmol) was stirred in t-BuOH/water mixture (1:2) at room temperature for 
2 d. Then, the reaction mixture was extracted with ethyl acetate three times. The 
combined organic layers were dried over sodium sulfate. The solvent was 
evaporated under reduced pressure to give 17a as a brown solid. 
 
3-(4-methylphenyl)-4-(5-((5-phenyl-1H-1,2,3-triazol-1-yl)methyl)-1,2,4-
oxadiazol-3-yl)sydnone (17a) 
 
Yield: 0.060 g, 90%. mp 129–131 °C. Rf: 0.21 (n-hexane:ethyl acetate; 1:1). IR (KBr, v:cm 1): 
3047, 2935, 1780 (sydnone C=O), 1625, 1568 (C=N), 1450, 1338, 1232, 1068, 908, 815, 761. 
1H NMR (400 MHz, CDCl3): δH ¼ 7.88 (s, 1H), 7.80 (d, J ¼ 7.2 Hz, 2H), 7.44 (t, J ¼ 7.2 Hz, 
2H), 7.40–7.34 (m, 3H), 7.29 (d, J ¼ 8.4 Hz, 2H), 5.85 (s, 2H), 2.34 (s, 3H). 13C NMR (100 MHz, 
CDCl3): δC ¼ 167.4 (sydnone C=O), 164.8 (C=N), 143.7, 131.5, 130.2, 129.7, 128.9, 
  
 
128.6, 125.7, 124.6, 124.1, 120.2, 96.8, 45.0 (CH2), 21.4 (CH3). LC–MS (80 eV) 
(m/z) (%): 424 ([MþNa]þ, 83), 402 ([MþH]þ, 100), 282 (93). ESI-MS (80 eV) (m/z) 
(%): 400 ([M H] , 100). HRMS: m/z (ESI-TOF, [MþH]þ) calcd for C20H16N7O3: 
402.1315; found: 402.1296. 
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